メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ

Management of pilomyxoid astrocytomas: Our experience

  • Hitoshi Tsugu
  • , Shinya Oshiro
  • , Fumio Yanai
  • , Fuminari Komatsu
  • , Hiroshi Abe
  • , Takeo Fukushima
  • , Yuko Nomura
  • , Shinji Matsumoto
  • , Kazuki Nabeshima
  • , Koichi Takano
  • , Hidetsuna Utsunomiya

研究成果: ジャーナルへの寄稿学術論文査読

抄録

Background: Pilomyxoid astrocytoma (PMA) shows a higher rate of recurrence and cerebrospinal fluid (CSF) dissemination than does pilocytic astrocytoma (PA). In this article, we discuss the treatment of PMA. Materials and Methods: Between 1992 and 2007, the authors treated 5 patients. Two of these were male, three female. Their ages ranged from 3 months to 11 years. Results: Three patients showed CSF dissemination on the initial radiographic examination. All patients received chemotherapy; the most commonly used combination drugs were cisplatin (CDDP)/carboplatin (CBDCA) and etoposide. When these drugs were unsuccessful, they were changed or other drugs added to the combination. After chemotherapy, four patients showed remarkable tumor regression. Nevertheless, one patient died 22 months after initial diagnosis, due to tumor progression. Conclusion: While our series was limited to a small number of patients, we have a positive impression of the value of chemotherapy. Even if initial chemotherapy is ineffective, we recommend continued CDDP/CBDCA-based chemotherapy with new drug combinations.

本文言語英語
ページ(範囲)919-926
ページ数8
ジャーナルAnticancer research
29
3
出版ステータス出版済み - 03-2009
外部発表はい

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

  1. SDG 3 - すべての人に健康と福祉を
    SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究

フィンガープリント

「Management of pilomyxoid astrocytomas: Our experience」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル